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ABSTRACT
Tumour necrosis factor (TNF), released by induced macrophages, causes
tumour necrosis in animals and kills preferentially transformed cells in
vitro. mRNA induced in the established mouse monocytic PU 5.1.8 cell line by
lipopolysaccharide, was converted into double-stranded cDNA and cloned in the
pAT153 vector. Recombinant plasmids were screened by plus-minus hybridization
and TNF-specific oligonucleotide probes constructed on the basis of partial
amino acid sequences of rabbit TNF. A series of TNF specific clones were
identified and confirmed by hybrid selection of mouse TNF-specific mRNA. The
sequence codes for a 235 amino acids long polypeptide, of which 156 amino
acids presumably correspond to the mature product. It can be concluded that
mature mouse TNF is a glycosylated dimer. Biologically active TNF was
secreted by both Cos-I and CHO-cells transfected with the chimaeric
expression vector pSV2d2-mTNF containing the coding region of the mouse TNF
cDNA gene.
INTRODUCTION
The antitumour effect of endotoxins has been known for over a century
because of remarkable observations regarding spontaneous regression of
certain human tumours following some bacterial infections (1,2). That tumour
regression could be attributed to a serum factor elicited by endotoxin was
proposed by Carswell et al. (3). TNF has so far mainly been prepared by in
vivo induction of the protein in mice or rabbits. The best way to produce TNF
was to inject the animals with Bacillus Calmette- Guerin (BCG) or
Corynebacterium parvum, followed by endotoxin (lipopolysaccharide, LPS) 1 to
2 weeks later (3, 4, 5). Mannel et al. (6), first reported in vitro induction
of mouse TNF in macrophage-enriched populations derived from BCG infected
mice, in peritoneal macrophages propagated with macrophage growth factor and
in the macrophage-like tumour cell line PU 5.1.8. Partially purified TNF
causes necrosis of some tumours in vivo and rather specifically kills many
transformed cells in tissue culture. Upon purification, multiple size forms
sharing similar physico-chemical properties such as heat stability and
sensitivity towards proteases, but distinct in cytotoxic and necrotizing
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activities can be segregated (7). Conclusive answers as to whether the in
vitro cell killing effect of TNF is due to the same factor as that which
causes haemorrhagic necrosis in vivo must await the unlimited availability of
the pure product. Moreover, although the cell source of lymphotoxin
(lymphocytes) and TNF (macrophages) is different, the mechanism of cytotoxic
action, species near-independence, influence of growth inhibitors on the
sensitivity of the cells, and stimulation of RNA synthesis in target cells
(8) are shared by both products. Furthermore, the fairly high selectivity of
both products for a variety of tumour cells (9) is most intriguing. The
differences and similarities in gene structure, organization and biological
properties of the two products will be better understood when the genes have
been cloned and expressed. We describe here the characterization of mouse TNF
mRNA and the cloning, molecular structure and eukaryotic expression of a
plasmid coding for mouse TNF. The amino acid sequence of the mouse TNF
protein, deduced from the nucleotide sequence analysis is presented. Very
recently, the cloning and expression of human lymphotoxin cDNA (10) and of
human TNF cDNA (11, 12) have been reported.
MATERIALS AND METHODS
In vitro induction of mouse TNF and TNF assay
Mouse TNF was induced in the mouse monocytic cell line PU 5.1.8
essentially as described by Mannel et al. (6). The cells were grown in RPMI
1640 medium enriched with 10% FCS (low endotoxin content - 309 Gibco
011-6309) in roller bottles, stimulated at a concentration of 3.5 x 106
cells/ml with 5 m.g LPS/ml in RPMI 1640 for 4 h and collected by centri-
fugation. TNF activity in the medium was assayed on L-929 cells in the
presence of actinomycin D (13). Serial dilutions of the TNF-containing
fraction were prepared in microtitre plates in Dulbecco medium - 10% FCS.
Fifty thousand L-929 cells and actinomycin D to a final concentration of
1 ug/ml were added to each well. Incubation took place at 370C or at 39.50C
for 18 h (the sensitivity is 2.5 times higher at 39.50C than it 370C). At the
end of the incubation period, the cells were fixed, stained (0.5% crystal
violet, 8% (v/v) formaldehyde (40%), 0.17% NaCl, 22.3% (v/v) ethanol) and
counted. For certain experiments, stained cells were eluted in the microtitre
plate in 33% acetic acid and the released dye was measured with a Kontron
Spectrophotometer (577 nm). One TNF unit (U)/ml represents the reciprocal of
the dilution of TNF required to reduce cell survivial by 50% within 18 h in
the killing assay performed in the presence of actinomycin D.
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Isolation of TNF mRNA and construction of a mouse cDNA library
For mRNA preparation, cells were lysed with 1% Nonidet-P40 in 0.1 M
NaCl, 0.01 M Tris-HCl pH 8.5, 0.003 M MgC12, treated with proteinase K,
extracted with phenol-chloroform-isoamyl alcohol (25:24:1), precipitated
twice and purified over oligo-dT cellulose (Type 3-Collaborative Research).
Poly A+-RNA was further fractionated on a 5-20% sucrose gradient (Beckman
SW41 rotor, 4°C, 40K, l9h) and TNF mRNA was identified by injecting aliquots
of each fraction into Xenopus laevis oocytes (50 nl mRNA per oocyte i 15
oocytes per sample) essentially as described by Devos et al. (14) except that
the oocyte bathing medium also contained lmM CuSO4 and incubation time was
reduced to 24 h. cDNA was prepared starting from 8 pg 17 S mRNA. Conditions
for first-strand synthesis and subsequent removal of the RNA template was
essentially as described by Devos et al. (15) except that for synthesis 750
U/ml human placental RNase inhibitor and 1000 U/ml AMV reverse transcriptase
were used. Second-strand synthesis and S -nuclease treatment were carried out
essentially as described by Maniatis et al. (16). Double stranded cDNA was
size-fractionated on a Sepharose CL 4B column to enrich for fragments larger
than approximately 500 bp. The resulting cDNA was inserted into the PstI site
of pAT153 by G-C tailing and transformed into E.coli DH1 (A) according to
Hanahan (17). The transformation mixture was plated on Millipore HATF (0.45
pM) filters that were layered on top of Luria broth agar plates containing 10
pg/ml tetracycline. Filters were stored on fresh plates also containing 20%
glycerol at -200C.
Screening of the mouse cDNA bank
Replicas of the mouse cDNA library were made according to Hanahan and
Meselson (18). Two sets of replicas were screened by plus-minus hybridi-
32
zation5 the plus probe being a P-labelled cDNA synthesized from the sucrose
gradient fractions of mouse poly A+-RNA which showed the highest TNF
biological activity after oocyte injection, the minus probe being eDNA
synthesized on an equivalent fraction obtained from uninduced cultures.
Colony hybridization was essentially as described by Maniatis et al. (16).
Plasmid DNA was extracted by the method of Birnboim and Doly (19), insert DNA
was separated from the plasmid by restriction with PstI, followed by gel
electrophoresis, and subsequently transferred and fixed on Millipore
nitrocellulose filters as described by Southern (20). Partially overlapping
probes were chemically synthesized (21, 22) and radioactively labelled to
high specific activity (> 5 x 108 cpm/pg DNA) by a filling-in synthesis using
Klenow polymerase in the presence of all four (o)-32P-labelled deoxynucleo-
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side triphosphates. Heterologous hybridization was performed in 25 mM sodium
phosphate buffer (pH 6.5) in the presence of 20% formamide at 420C.
Hybridization-translation assay
Plasmid DNA of plus-minus-selected cDNA clones was isolated according to
Pulleyblank et al. (23). Of each preparations about 30 ug was cleaved with
the EcoRI restriction enzyme and bound to a membrane essentially as described
by Kafatos et al. (24), except that Gene Screen (NEN, Boston, MA) was used
instead of nitrocellulose filters, the ammonium acetate concentration
increased from 1 M to 2 M, and the filters not baked but treated under UV
light according to Church and Gilbert (25). The hybridization with
TNF-positive poly A+-RNA and subsequent RNA elution was essentially as
described by Parnes et al. (26), except that the RNA was eluted in the
presence of 5 ug poly A_-RNA (oligo (dT)-cellulose run-through fraction) and
that instead of a phenolization step, the RNA was precipitated twice with
ethanol.
Insertion of the TNF cDNA sequence in an eukaryotic expression vector and
transfection
The purified NarI-EcoRI fragment of the mouse cDNA gene (clone p-mTNF-3)
was blunt-ended by the Klenow large fragment of E. coli polymerase I and
provided with SalI linkers using T4-ligase. This fragment was then inserted
in the unique SalI site of pSVd2-3. Cos-I cells were transfected with the
recombinant expression vector essentially as described by Gheysen and Fiers
(27), except that immediately after transfection, the cells were incubated
for 4 h in medium containing 0.1 M chloroquine (28) and subsequently treated
overnight with 1 mM sodium butyrate (29). Co-transfection of the CHO DHFR
cells with the recombinant expression vectors pSVd2-3 mTNF and pAdD26SV(A)-3
in a ratio of 10:1 was essentially as described by Scahill et al. (30).
RESULTS
Construction of bacterial clones containing mouse TNF cDNA sequences
In vitro induced PU 5.1.8 cells were used for isolation of TNF-specific
mRNA. The medium usually contained TNF activities of 4 - 6 x 103 U/ml and
about 10 mg of total RNA was obtained from 109 lysed cells of which 2%
represented polyadenylated (poly A+)-RNA. This mRNA fraction was further
enriched by sedimentation through a neutral 5 - 20% sucrose gradient (Fig.
1). The amount of TNF-specific mRNA was monitored by translation in Xenopus
laevis oocytes followed by an assay of the TNF activity released in the
bathing medium. The peak fraction migrated at 17 S and resulted upon
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Fig. 1 Fractionation of TNF mRNA by
sucrose density gradient sedimenta-
tion. LPS stimulated PU 5.1.8. cells
were lysed with 1% Nonidet-P40, trea-
iss ted with proteinase K, extracted with
phenol-chloroform-isoamylalcohol pre-
- .80 cipitated twice and purified over
E
Ir .1 \ .256 oligo-dT cellulose.Two hundred twenty-
-60 2 < five ,ug of poly A -RNA was further
c.6 l0 128 fractionated on a 5-20% sucrose
64^ gradient. Fractions of 10 drops wereE
.40 32 _ collected, ethanol precipitated and
5S / the RNA dissolved in 20 ul H20. The16
_
RNA was translated in Xenopus laevis
20 / | 8 oocytes and the TNF activity in the
i4 bathing medium was measured on L-929
.____.____________ cells at 39.50C in the presence of
fraction n- actinomycin D.
translation in 150-300 TNF U/ml. This fraction was used for the synthesis of
double-stranded cDNA and cloning. Approximately 30,000 clones were obtained
in this way of which 90% were ampicillin-sensitive indicating the presence of
a cDNA insert.
Isolation and characterization of a mouse cDNA clone
About 5,000 colonies of the mouse cDNA library were subjected to a
plus-minus hybridization screening to identify clones containing an
induction-specific cDNA insert. About 2% of the clones hybridized with the
plus probe only. These positives were chosen for a second round of plus-minus
hybridization. In this way, 55 mouse clones corresponding to induced genes
were finally selected. Plasmid DNA was individually extracted from these 55
plus-minus preselected cDNA clones and further pooled into 11 groups of 5
clones. The insert DNAs were separated from the plasmids by cleavage using
the PstI restriction enzyme followed by agarose gel electrophoresis, and were
subsequently transferred and fixed on nitrocellulose filter. Two sets of
partially overlapping probes (Fig. 2, fragments 3 and 4) (31), corresponding
to the known amino acid sequence of two CNBr-fragments derived from highly
purified rabbit TNF (described elsewhere), were chemically synthesized and
radioactively labelled by filling-in with Klenow polymerase in the presence
of (CA)-32P-nucleoside triphosphates. Duplicate filters were hybridized with
probe 3 or 4, respectively. One group gave a positive hybridization signal
with the probe derived from the rabbit TNF protein CNBr-fragment 3, and this
result was confirmed at the individual clone level (in fact two individual
cDNA clones were found positive in this group, but they turned out to be
identical). This clone is further indicated as p-mTNF-1. Two additional mouse
4421
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TNF FRAGMENT 3
MetLysLeuThrAspAsnGlnLeuValValProAlaAspGlyLeuTyrLeulleTyr
TNF 3-1
ATGAAACTMACMGACAACCAACTMGTHGTMCCMGCMG
CAKGGKOCGKCTGCCKGAKATGGAKTAKATCTTAA
TNF 3-4
TNF FRAGMENT 4
MctAlaTrpTyrGluProlleTyrLeCuGlyGlyValPheGlnLeuGluLysGlyAspArgLeu
TNF 4-1
TGGTACGAACCMATMTACCTMGGCCGGGTCTTC
GCAGAAGGTTGAKCTTTTTCCKCTCTCATTAA
TNF 4-4
M = A. C ; K = C, T
Fig. 2 Partial amino acid sequences of two CNBr-fragments (3 and 4) of highly
purified rabbit TNF. Two partially overlapping nucleotide probes (TNF 3-1 and
TNF 3-4; TNF 4-1 and TNF 4-4, respectively), coding for the indicated amino
acid sequence, were synthesized and radioactively labelled to high specific
activity by f ling-in synthesis using Klenow polymerase in the presence of
all four (0Q- P-labelled deoxynucleoside triphosphates.
TNF-specific cDNA clones (p-mTNF-2 and -3) were identified among the 55
plus-minus selected clones by hybridization with a nick-translated
(c-32P-labelled RsaI-fragment derived from the insert DNA of p-mTNF-1 (Fig.
4a).
Experiments showing that mouse cDNA clones specifically hybridized to
TNF mRNA further demonstrated that the clones, selected by heterologous
hybridization, in fact, contained TNF-specific sequences. Plasmid DNA was
isolated from pools of the 55 plus-minus selected cDNA clones, each pool
containing 6 or 7 individual clones. Approximately 30 ug of each preparation
was cleaved with the EcoRI restriction enzyme, bound to a membrane and
hybridized with TNF-positive poly A+-RNA. Eluted RNA was assayed by injection
in Xenopus laevis oocytes. Three pools scored positive in this hybridization-
translation assay. These same pools turned out to contain p-mTNF-1, p-mTNF-2
and p-mTNF-3, respectively. Therefore, these three individual plasmids were
tested again and all three were able to selectively hybridize with TNF-mRNA.
Restriction analysis indicated that all three cDNA clones (p-mTNF-1, -2
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Fig. 3 pSV2d2-3, a modified pSV2 vector (35) was used for expression in
eukaryotic cells; pSV2d2-3 contains the EcoRI-AvaI-fragment of pAT153
(poison-minus derivative), the PvuII-HindIII eriaincer early promotor-
ori-region of SV40 directly followed by the linker sequence HindIII-XbaI-SalI
and followed by the SV40 small-t splicing signal and the SV40 polyadenylation
region. The purified NarI-EcoRI fragment of the mouse cDNA gene (clone
p-mTNF-3) was blunt-ended by the Klenow large fragment of E. coli polymerase
I and provided with SalI linkers using T4-ligase. This fragment was then
inserted in the unique SalI site of pSV2d2-3. Transfection of Cos-I and CHO
cells was as described in Materials and Methods.
and -3) were derived from the same type of mRNA and, hence, almost certainly
from the same gene. Digestion with PstI revealed that p-mTNF-1, 2 and -3
contained an insert of 1,550, 350 and 1,000 bp, respectively. The complete
nucleotide sequence was deduced by sequencing both p-mTNF-1 and -3 using the
Maxam-Gilbert procedure (32). Fig. 4a. shows a general outline of the cDNA
gene and a map of some deduced and experimentally verified unique restriction
sites.
Eukaryotic expression of mouse recombinant TNF
Final confirmation that the clone we had isolated does code for active
TNF was shown by eukaryotic expression in both transfected Cos-I cells (33)
and CHO cells (34) and by subsequent characterization of the resulting
product in the L-929 assay system. For this purpose the NarI-EcoRI fragment
of the mouse cDNA gene (clone p-mTNF-3) was purified and inserted in the
unique SalI of the expression vector pSV2d2-3, a modified pSV2 vector (35).
In the resulting chimaeric expression vector pSV2d2-3 mTNF (Fig. 3), the TNF
cDNA sequence is under transcriptional control of the SV40 early promotor
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sequence and followed by the SV40 small-t splicing signal and SV40
polyadenylation signal. Both orientations of the mouse TNF gene with respect
to the SV40 early promotor were tested. In the samples taken 72 and 96 hours
after transfection of the Cos-I cells, TNF activity was present in the
supernatants of the sense-orientated construction but not in the supernatants
of anti-sense constructions. Co-transformation of CHO DHFR cells with
pAdD26SV(A)-3 and pSV2d2-3 mTNF in a molar ratio of 1:10 and the subsequent
selection of transformed cells by virtue of their DHFR+ phenotype essentially
as described by Scahill et al. (30) resulted in a set of transformants which
secreted TNF activity (30 U/ml).
DISCUSSION
Conditions have been optimized for induction of TNF in the mouse
monocytic cell line PU 5.1.8. mRNA from the induced cells was then used as
a source for molecular cloning. The resulting mouse cDNA library was first
subjected to a plus-minus hybridization screening to identify clones
containing an induction specific cDNA insert. Mouse TNF cDNA clones were
identified among the preselected plus clones by hybridization with a
TNF-oligonucleotide probe constructed on basis of partial amino acid
sequences of rabbit TNF (purification and chemical characterization of rabbit
TNF will be described elsewhere). Hybridization elution experiments confirmed
the TNF specificity of the clones. Finally, proof that the isolated clone
coded for TNF was obtained by biological expression. Transfection of Cos-I
cells and CHO cells with pSVd2-3 mTNF containing the complete mouse cDNA TNF
gene under control of the SV40 early promotor sequence led to secretion of
TNF activity in the medium. Approximately 0.1% of the clones from the mouse
cDNA bank hybridized to the internal mouse TNF-specific 252 basepair RsaI
fragment (Fig. 4a). As the mRNA used for cloning was 10-15 fold enriched by
sucrose gradient centrifugation, we estimate that approximately I out of
10,000-15,000 mRNA molecules is TNF-specific under the condition used for
induction in PU 5.1.8. cells. The nucleotide sequence, shown in Fig. 4b,
predicts a large open reading frame starting from the first ATG at position
157, specifying a polypeptide of 235 amino acids. The untranslated 5'-region
in the cDNA is 156 nucleotides long but presumably incomplete considering the
method used for the in vitro synthesis of double-stranded cDNA. The
3'-untranslated region is 780 nucleotides long and may be complete
considering the presence of two potential AATAAA polyadenylation signals at
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the end of the sequence. Based on amino-terminal amino acid sequence data
obtained on highly purified human TNF secreted by phorbol ester-induced U-937
cells (manuscript in preparation), a presequence of 79 amino acids may be
cleaved off between Thr79_Leu80 of the precursor to obtain the mature mouse
TNF protein of 156 amino acids3 the exact position of the N-terminal amino
acid of mouse TNF, however, is not known and should be verified by direct
characterization of the mature protein. A remarkably large homology exists in
both the prepeptide (86%) and the mature protein (79%) region between the
amino acid sequence of mouse and human TNF (described elsewhere). This large
sequence homology between the two TNF proteins may be related to the nearly
complete lack of species specificity of the biological action of TNF. The
presequence (79 amino acids) is unusually long for a transmembrane signal3 we
do not yet know whether this is removed in a single step or whether parts of
this segment fulfill a special role. Usually, a signal peptide is 20-30 amino
acids long, contains one or more basic residues near the N-terminus and a
highly hydrophobic part in the central region. The presequence contains a
central region that is highly hydrophobic (from Leu31 to Ile56) but as many
acidic as well as basic residues are present in the first 30 amino acids.
Mouse TNF has been shown to be a glycoprotein (36), while human TNF is not
(data not shown). Attachment of carbohydrate by N-glycosydic linkage is known
to occur on the asparagine in the triplets Asp-X-Ser/Thr. Indeed, a potential
N-glycosylation site of this type can be identified in mouse TNF at position
86 of the precursor sequence while this site is not conserved in the human
sequence. The deduced mature mouse protein of 156 amino acids corresponds to
a calculated Mr of 17,200 (without the glycosyl group). Characterization of
the mouse macrophage TNF product revealed that it has an apparent Mr of
150,000 (7, 36) but this might be an aggregated form in the serum because
partial purification in high ionic strength buffer allowed the identification
of a Mr 55,000 active protein on gel filtration (6). Gel filtration of human
TNF under the same conditions revealed a protein of Mr 35,000, while on a
sodium dodecylsulphate-polyacrylamide gel, a Mr 17,500 protein band could be
identified (11). Therefore, it seems most likely that the native, mature,
unglycosylated human TNF is a dimer, as well as the glycosylated mouse TNF.
Analogous results with human interferon gamma were previously obtained, where
it was shown that the mature protein also exists as a dimer (37). Two
cysteines (at positions 148 and 179 in the precursor) may be involved in an
intrasubunit disulphide bridge. Indeed the two subunits in the dimer
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presumably are not held together by covalent linkages as the same Mr 17,500
band can be detected on a sodium dodecylsulphate-polyacrylamide gel under
reducing as well as non-reducing conditions. Furthermore, mouse TNF activity
is inactivated by treatment with dithiothreitol (7), suggesting that the
cystine-bond might be required for biological activity. The isolation of a
cDNA clone encoding mouse TNF opens many new possibilities for further study
of this promising anti-cancer protein at a biochemical, molecular biological
and biological level. Especially intriguing are its mechanism of action and
the molecular basis for its apparent selective toxicity for transformed cells
in vitro and tumour necrotizing activity in mice. It should also allow
further investigation of the synergism with other lymphokines (38) and
various drugs. Hopefully, these preclinical data may open the way to an
evaluation of the potential application of human TNF in clinical medecine.
While this manuscript was being prepared, we learned of the results of
Pennica et al. (12), and Shirai et al. (39), who recently reported the
cloning and expression of human TNF. The nucleotide and amino-acid sequence
which they published is in complete agreement with our results on human TNF
(11).
Fig. 4a. Map of the mouse TNF mRNA and the isolated cDNA clones. The diagram
at the top represents the structure of the mouse TNF mRNA. The stippled box
indicates the corresponding putative signal peptide and the clear box
indicates the coding region for the mature mouse TNF polypeptide. The
estimated length in nucleotides of the 3'- and 5'-untranslated regions and
the putative prepeptide and mature protein coding sequences are also given.
(A)n indicates the 3'-poly(A)-tail. Lines underneath represent the regions of
the mouse TNF mRNA covered by the three isolated mouse cDNA clones p-mTNF-1,
-2 and -3, respectively. Wavy lines indicate the homopolymer tails used to
construct the cDNA clones. At the bottom, a map of most unique restriction
sites constructed from a computer search made on the complete nucleotide
sequence is presented. Also indicated (black bar) is the RsaI fragment which
was purified and used in further hybridization experiments.
Fig. 4b. Nucleotide sequence of the mouse TNF cDNA and its derived amino acid
sequence of the pre-TNF polypeptide. A continuous nucleotide sequence of 1644
nucleotides is presented. Full boxes indicate the start and stop codon,
dashed boxes indicate two putative AATAAA polyadenylation signals. Amino
acids are given in one letter code. The presequence is underlined (the
putative N-terminus has been chosen on the basis of analogy with the human
mature TNF sequence, indicated by an arrowhead). A glycosylation signal
corresponding to the sequence N-X-S/T, and two cysteine residues, believed to
be involved in an intramolecular disulphide bridge, are also indicated in
full boxes.
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